India takes giant leap forward in biopharma and space exploration

India’s annual budget has brought exciting news for the country’s biopharmaceutical and space sectors. The government has announced the launch of Biopharma Shakti, a ₹10,000-crore initiative aimed at making India a global hub for drug development. This five-year program will boost domestic production of biologics and biosimilars, critical for treating cancer, diabetes, and other diseases.

Key highlights:

1.Three new National Institutes of Pharmaceutical Education and Research

2. Upgrades to seven existing institutes1,000 accredited clinical trial sites nationwide

3. Strengthening of India’s drug regulator, CDSCO

The budget also sees a 2.16% increase in space spending, with ₹13,705.63 crore allocated to the Department of Space. This supports flagship missions like Gaganyaan and establishes new astronomy facilities, including the National Large Solar Telescope.”This is a game-changer for India’s biopharma sector,” says Taslimarif Saiyed, C-CAMP Bengaluru. “These facilities will anchor India’s solar physics and astrophysics research,” adds Dibyendu Nandi, IISER Kolkata.